Faculty Profiles - NASU Yasutomo

Papers - NASU Yasutomo

Division display 581 - 600 of about 612 ／ All the affair displays >>

Endoscopic removal of a spontaneously disrupted double J ureteral stent : A case report

Koichi Monden, Seiichi Itou, Ryuji Fujita, Masaya Tsugawa, Yasutomo Nasu, Hiromi Kumon, Hiroyuki Ohmori

Nishinihon Journal of Urology 58 ( 12 ) 1230 - 1232 1996

Language：Japanese Publishing type：Research paper (scientific journal)

We report a case, showing spontaneous disruption of a double J ureteral stent where the patient was subjected to endoscopic surgery. A 69-year-old woman had right hydronephrosis probably due to UPJ and UVJ stenosis. A double J ureteral stent (6Fr. 28cm, COOK) had been inserted at another institution. One month after the insertion, the ureteral stent spontaneously broke into 2 pieces. The stent then broke into 4 pieces 3 months later. She was admitted to our hospital for removal of the broken stent. We retrieved the stent through a semi-rigid ureteroscope (10.9Fr. OLYMPUS) using a 2-pronged grasper (5Fr. STORZ).

Scopus

researchmap

PSAにおけるsubtypeの研究 : その存在と各種PSA抗体に対する親和性の違いについて

野田雅俊, 津島知靖, 那須保友, 宮地禎幸, 大森弘之

日本泌尿器科学会雑誌 86 ( 3 ) 432 - 432 1995

尿路癌におけるアポトーシスについて : 臨床例におけるアポトーシスの発現

郭春鋼, 那須保友, 津島知靖, 大森弘之

日本泌尿器科学会雑誌 86 ( 3 ) 648 - 648 1995

フローサイトメトリーを用いた尿路移行上皮癌における細胞表面糖鎖抗原の定量化について

高松正武, 那須保友, 津島知靖, 大森弘之

日本泌尿器科学会雑誌 86 ( 1 ) 201 - 201 1995

前立腺肥大症に対するVLAPの臨床的検討 : 長期成績と合併症について

那須保友, 渡辺豊彦, 公文裕巳, 大森弘之, 入江伸, 西村元一, 金重哲三

日本泌尿器科学会雑誌 86 ( 1 ) 239 - 239 1995

前立腺癌における神経内分泌細胞(Neuroendocrine cell)の意義 : Chromogranin Aおよびneuron specific enolaseの発現と治療の反応性について

郭春鋼, 那須保友, 津島知靖, 大森弘之

日本泌尿器科学会雑誌 86 ( 1 ) 169 - 170 1995

尿路癌におけるアポトーシスについて : In vitroにおけるアポトーシスの誘導

那須保友, 郭春鋼, 津島知靖, 大森弘之

日本泌尿器科学会雑誌 86 ( 3 ) 648 - 648 1995

膀胱癌におけるフローサイトメトリーを用いた細胞表面糖鎖抗原の定量化について : レクチンサイトメトリー法の基礎的・臨床的検討

宮地禎幸, 高松正武, 那須保友, 津島知靖, 大森弘之

日本泌尿器科学会雑誌 86 ( 3 ) 644 - 644 1995

FISH法を用いた膀胱癌組織の染色体数的異常の検出

井上高明, 那須保友, 津島知靖, 大森弘之

日本泌尿器科学会雑誌 86 ( 3 ) 805 - 805 1995

腹腔鏡下精索静脈瘤手術の臨床的検討

永井敦, 大枝忠史, 秋山博伸, 小澤秀夫, 市川孝治, 那須保友, 公文裕巳, 大森弘之

日本泌尿器科学会雑誌 86 ( 3 ) 818 - 818 1995

THERAPEUTIC OUTCOME OF G-CSF THERAPY ON ADVANCED TESTICULAR TUMORS Reviewed

T TSUSHIMA, M TAKAMATSU, T SAIKA, Y MAKI, N AKEBI, Y NASU, H OHMORI

PROCEEDINGS OF THE XVI INTERNATIONAL CANCER CONGRESS - FREE PAPERS AND POSTERS, TOMES 1-4 2225 - 2229 1994

EPIDERMAL GROWTH FACTOR AS A MARKER FOR RECURRENCE OF THE BLADDER CANCER Reviewed

T SAIKA, T TSUSHIMA, Y NASU, M NODA, Y MORIYA, H OHMORI

PROCEEDINGS OF THE XVI INTERNATIONAL CANCER CONGRESS - FREE PAPERS AND POSTERS, TOMES 1-4 2145 - 2149 1994

OVER‐EXPRESSION OF METALLOTHIONEIN AND DRUG‐RESISTANCE IN BLADDER CANCER Reviewed

Takashi Saika, Tomoyasu Tsushima, Jyunzo Och, Naoki Akebi, Yasutomo Nasu, Yosuke Matsumura, Hiroyuki Ohmori

International Journal of Urology 1 ( 2 ) 135 - 139 1994

Language：English Publishing type：Research paper (scientific journal)

Metallothionein (MT) in tumor cells has been implicated as one of the factors involved in mechanisms of resistance to anti‐cancer drugs, including cis‐diaminedichroloplatinum (CDDP) and adriamycin (ADM). The relationship between the expression of MT and chemotherapy with anti‐cancer drugs was studied in CDDP‐ and ADM‐resistant human bladder cancer cell lines and tissue samples from clinical cases. In drug‐resistant cell lines (T‐24/ADM, CI‐7/CDDP) established in our laboratory, MT expression was studied by immunohistochemistry using the avidin‐biotin peroxidase complex (ABC) method and radioimmunoassay (RIA), using anti‐MT antibody. In addition, other potentfal mechanisms of drug resistance, such as P‐glycoprotein expression were examined and the levels of reduced glutathione (GSH), oxidized glutathione (GSSG) and glutathione‐S‐transferase (GST) determined in these cell lines. The results of these investigations demonstrate that the expression of MT in resistant cell lines increased 2.1‐ and 2.5‐fold when compared with parent cell lines (CI‐7, T‐24). GSH, GSSG and GST levels were unchanged and P‐glycoprotein was not over‐expressed. A total of 120 tissue samples from 35 clinical cases of bladder cancer, before and after chemotherapy, were stained for MT which was detected in 10 of the 35 cases before chemotherapy. The incidence of MT expression was significantly higher (p less than 0.05) in cases with lower pathological tumor grades. By analyzing the MT staining after chemotherapy in the cases whose MT staining was negative before chemotherapy, it was found that cases receiving continuous administration (intravesical chemotherapy or peroral chemotherapy) showed a higher incidence (9/13) of positive staining for MT, than patients receiving intermittent administration (intravenous chemotherapy) (1/8), (p less than 0.05). These results demonstrate that: 1) a correlation exists between MT expression and tumor differentiation and 2) repetitive and continuous administration of anti‐cancer drugs results in increased MT expression in bladder cancer cells. MT expression may therefore be one of the mechanisms by which urothelial tumors acquire resistance to anti‐cancer drugs. Copyright © 1994, Wiley Blackwell. All rights reserved

DOI： 10.1111/j.1442-2042.1994.tb00022.x

Scopus

PubMed

researchmap

Clinical study of urethral recurrence of superficial bladder cancer : its clinical significance as a prognostic implication

Nasu Y, Tsushima T, Akebi N, Maki Y, Takamatsu M, Inoue T, Ohmori H

J Urol 151 ( 5 ) 232A 1994

Therapeutic outcome of G-CSF therapy for the treatment of advanced testicular tumors

M. Takamatsu, T. Tsushima, Y. Nasu, M. Noda, T. Saika, S. Kaku, H. Ohmori

Nishinihon Journal of Urology 56 ( 12 ) 1508 - 1512 1994

Language：Japanese Publishing type：Research paper (scientific journal)

In the present study, we assessed the effect of granulocyte colony-stimulating factor (G-CSF) on patients with advanced testicular tumors. The subjects were 24 patients with stage II B or higher, advanced testicular tumors treated in the Department of Urology, Okayama University Hospital during the 12-year period from 1980 to 1991 (5, stage II B and 19, stage III: 19 primary cases and 5 recurrent cases). We compared the intensity of the CDDP dose against prognosis in 24 patients, 12 of whom were treated prior to 1986 when G-CSF had not been available, the other 12 patients being treated after 1987 using G-CSF. The CDDP dose intensity was increased significantly from 16.9-32.2 mg/m2/wk (20.6 ± 6.2 mg/m2/wk, mean ± SD) to 20.9-37.0 mg/m2/wk (29.6 ± 5.2 mg/m2/wk) after the introduction of G-CSF (t-test, p &lt
0.001). The 5-year survival rate was 40% in those patients treated without G-CSF as opposed to 90% after the introduction of G-CSF, and this result was statistically significant (logrank test, p = 0.04). Before the introduction of G-CSF, adverse reactions such as leukocytopenia forced us to reduce the doses and to change the schedules. Chemotherapy could be performed at full doses and on schedule due to the concomitant use of G-CSF, with the result that the therapeutic outcome was much improved.

Scopus

researchmap

Hyperthermotherapy Added to the Multidisciplinary Therpay for Penile Cancer

Kuroda M, Tsushima T, Nasu Y, Asaumi J, Nishikawa K, Gao X.S, Joja I, Takeda Y, Togami I, Makihata E, Kawasaki S, Ohmor H, Hiraki Y

Acta Med. Okayama 47 ( 3 ) 169 - 174 1993

Endopyeloplasty for ureteropelvic junction obstruction with a new, multifunction surgical endoscope in children

KUMON H.

Jpn J Endourol ESWL 6 ( 1 ) 35 - 38 1993

Tissue concentration of intravesically instilled (2″R)-4′-0-tetrahydropyranyl-adriamycin or adriamycin in superficial bladder cancer Reviewed

Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Masatoshi Noda, Naoki Akebi, Syunko Kaku, Masatake Takamatsu, Hiroyuki Ohmori, Satoru Uno, Taiichiro Johsen

Japanese Journal of Urology 84 ( 7 ) 1206 - 1210 1993

Language：English Publishing type：Research paper (scientific journal)

Twenty-one patients with superficial bladder cancer entered an analysis of single dose (2′R)-4′-0-tetrahydropyranyladriamycin (THP) or adriamycin (ADM) administration. The patients in each group that have been or not have been treated previously with anti-cancer drugs were randomized into two groups, one was given THP and the other ADM. Thirty-mg of THP or ADM dissolved in 30 ml of physiologic saline was instilled into the bladder, and retained for 1 hour. After 1 hour retention of the drugs, tumor tissues and normal mucosas were removed by punch biopsy forceps transurethrally. The tissue concentrations of THP and ADM were estimated by high performance liquid chromatography. The tissue concentrations of THP and ADM in the tumors were significantly greater (p&lt
0.05) than those in the normal bladder mucosas. The tissue concentration of THP in the tumors were greater than that of ADM. The tissue concentrations of THP and ADM in the tumor of patients who have been treated with anti-cancer drugs priviously were less than those of patients who have not. This results demonstrated that prior therapy with anti-cancer drug may cause a resistance for intravesical instillation chemotherapy. However in patients with prior therapy, the tissue concentration of THP in the tumors were greater than that of ADM. Based on these findings, THP has been shown to be were effective as an intravesical instillating agent expecially, in cases with prior chemotherapy. © 1993, THE JAPANESE UROLOGICAL ASSOCIATION. All rights reserved.

DOI： 10.5980/jpnjurol1989.84.1206

Scopus

PubMed

researchmap

膀胱腫瘍におけるMalignant potentialの指標としてのABH-isoantigen-PCNA, c-erb B-2との関連について : 第80回日本泌尿器科学会総会

郭春鋼, 那須保友, 津島知靖, 明比直樹, 野田雅俊, 高松正武, 大森弘之

日本泌尿器科学会雑誌 84 ( 1 ) 178 - 178 1993

腎細胞癌患者と職業歴の関連性に関する検討 : 溶接歴と腎細胞癌発生について : 第80回日本泌尿器科学会総会

野田雅俊, 津島知晴, 那須保友, 明比直樹, 郭春鋼, 高松正武, 大森弘之, 岡田茂, 松村陽右

日本泌尿器科学会雑誌 84 ( 1 ) 211 - 211 1993

　 PREV - NEXT 　

< NASU Yasutomo >

Papers - NASU Yasutomo